Publicaciones en las que colabora con Esteban Martínez Chamorro (27)

2023

  1. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

    Clinical Microbiology and Infection, Vol. 29, Núm. 1, pp. 85-93

  2. Hepatitis delta infection among persons living with HIV in Europe

    Liver International, Vol. 43, Núm. 4, pp. 819-828

2022

  1. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

    HIV Medicine, Vol. 23, Núm. 6, pp. 684-692

  2. Observational cohort study of rilpivirine (RPV) utilization in Europe

    AIDS Research and Therapy, Vol. 19, Núm. 1

  3. Past and future of HIV infection. A document based on expert opinion

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 35, Núm. 2, pp. 131-156

  4. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

    AIDS (London, England), Vol. 36, Núm. 15, pp. 2171-2179

  5. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

    HIV Medicine, Vol. 23, Núm. 6, pp. 585-598

2021

  1. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

  2. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy

    Annals of internal medicine

  3. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 87, Núm. 2, pp. 806-817

2020

  1. Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons

    Epidemiology

  2. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study

    Annals of internal medicine, Vol. 173, Núm. 7, pp. 536-541

2019

  1. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 151-159

  2. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    HIV Medicine, Vol. 20, Núm. 4, pp. 264-273

  3. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

2018

  1. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276

2016

  1. Human immunodeficiency virus as a chronic disease: Evaluation and management of nonacquired immune deficiency syndrome-defining conditions

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  3. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5